FusionPharm, Inc (FSPM) Fair Value & Analysis
Healthcare · US · Market cap $1.1K
FusionPharm, Inc
FSPM · US
Fair value as of: Aug 17, 2026
From 6 valuation models · updated yesterday
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.
How to read this chart
60‑month range $0.0001 – $0.2000 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 17, 2026.
Analysis
FusionPharm, Inc (FSPM) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at $329K. Fundamentals as of Aug 17, 2026
The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 0%, FSPM screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: DCF Models ($0.0004) versus Multiples ($0.0001). Highest evidence: Growth DCF (80).
Notify me when FSPM reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 72 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. Its PharmPods cultivation container system is used in the indoor plant cultivation. The company also offers its products to businesses, universities, and individuals to cultivate various plants. FusionPharm, Inc.
Full company description
FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. Its PharmPods cultivation container system is used in the indoor plant cultivation. The company also offers its products to businesses, universities, and individuals to cultivate various plants. FusionPharm, Inc. was formerly known as Baby Bee Bright Corp. and changed its name to FusionPharm, Inc. in April 2011. The company is based in Commerce City, Colorado.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2006 – FY2013 · reported fiscal years
FusionPharm, Inc reported revenue of $594K in FY2013 versus $22.3K in FY2006, a compound +59.9%/yr. Reported net income was −$42.1K in FY2013.
Watch FSPM: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 63 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | -14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.33 | HK$2.04 | -39% |
| Raia Drogasil S.A RADL3 | R$18.00 | R$15.58 | -13% |
| Yifeng Pharmacy Chain Co 603939 | ¥24.03 | ¥29.07 | +21% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.14 | ¥23.86 | +32% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 726.02 MXN | +57% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | -21% |
| MedPlus Health Services Limited MEDPLUS | ₹675.05 | ₹379.25 | -44% |
| Yixintang Pharmaceutical Group 002727 | ¥12.29 | ¥9.45 | -23% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.51 | ¥10.05 | -39% |
Compare FusionPharm, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is FusionPharm, Inc (FSPM) overvalued or undervalued?
What is the fair value of FSPM?
What is the quality score of FSPM?
What is the revenue of FusionPharm, Inc (FSPM)?
What is the net profit margin of FSPM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track FusionPharm, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.